Atopic Dermatitis

Strategies used to evaluate patients and accurately diagnose atopic dermatitis in children and adults.

Experts in dermatology discuss patient education and clinical pearls to assist colleagues in the management of atopic dermatitis.

The authors of a recent review recommend continued research on “powerful” new treatment methods that are effective in treating atopic diseases such as atopic eczema.

Investigators believe their study shows the efficacy and safety of the 2 biologic agents, which are known to have anti-inflammatory and immunosuppressant qualities.

Margaret Bobonich, DNP, FNP-C, DCNP, FAANP, and Douglas DiRuggiero, DMSc, PA-C, provide insight into the emerging class of JAK inhibitors for atopic dermatitis including their pathophysiology, route of administration, and available clinical evidence.

Patient factors and disease characteristics that impact one’s treatment approach for atopic dermatitis.

Key players in dermatology clinics and steps taken to help patients receive access to newer therapies available to treat atopic dermatitis.

Margaret Bobonich, DNP, FNP-C, DCNP, FAANP, and Douglas Di Ruggiero, DMSc, PA-C, provide an overview of current and emerging systemic therapies for atopic dermatitis.

The good care practices cited in the study can lead to increased care of patients with atopic dermatitis and are able to be implemented in any practice.

Recent data from phase 3 clinical trials of the antibody shows significant skin clearance and itch in people with atopic dermatitis.

Reactions to the efficacy and safety of dupilumab treatment for atopic dermatitis as demonstrated by clinical trial data and real-world experience.

Experts in dermatology describe the topical treatment landscape of atopic dermatitis: corticosteroids, calcineurin inhibitors, crisaborole, and upcoming topical JAK inhibitors.

Keri Holyoak, PA-C, MPH, reacts to the FDA approval of dupilumab for atopic dermatitis and explains what makes this therapy unique compared to other treatment options.

Margaret Bobonich, DNP, FNP-C, DCNP, FAANP, and Douglas DiRuggiero, DMSc, PA-C discuss best practices in the non-pharmacologic management of atopic dermatitis including elimination of triggers, bathing, and reducing infection risk.

According to a claims analysis, sunburn was also commonly diagnosed in female and young patients.

Investigators link early atopic manifestations and other complications to tree nut allergy, which account for most of all food related deaths by anaphylaxis.

The prevalence of striae distensae was notably higher in psoriasis than atopic dermatitis.

Dr. Blauvelt speaks on the results of the phase 3b Heads Up study, and the future of upadacitinib and dupilumab in atopic dermatitis management.

The rationale for using systemic therapies such as methotrexate, azathioprine, phototherapy, or others to treat patients with severe, persistent atopic dermatitis.

Best practices using topical therapies to treat atopic dermatitis and managing treatment-related adverse events.

Brett King, MD, PhD, encourages dermatologists to wait for more clinical data before making any assumptions on the drug class' safety and selectivity.

Brett King, MD, PhD, compares the efficacy of JAKs with biologics in the atopic dermatitis setting.

Brett King, MD, PhD, provides an overview of JAK inhibitors and their interaction with the JAK-STAT pathway.

Non-pharmacological strategies that can help patients with atopic dermatitis cope with symptoms and advice to help healthcare professionals counsel patients on proper use of these products and techniques.

Recommendations on educating primary care physicians about atopic dermatitis and the importance of early referral to dermatologists.

Studies are needed to determine the best treatment regimen for these patients.

A recent statement by Regeneron noted that chronic spontaneous urticaria is the fifth disease associated with positive Phase 3 results involving the monoclonal antibody.

The selective topical PDE4 inhibitor demonstrated rapid improvements in IGA and EASI scores and high tolerability in pediatric populations.

On the latest Derm Discussions, Brett King, MD, PhD, joins Brad Glick, DO, to discuss the potential of the JAK inhibitor class for dermatology.